PSMA*CD3

JANX reported data from the dose escalation portion of its Phase 1a trial of JANX007 to treat advanced prostate cancer. JANX007 reduced PSA levels in most 23-dosed patients, with deeper reductions observed at higher doses. PSA is a protein produced by the prostate gland and used as a biomarker to diagnose and follow prostate cancer.

潜在并购品种。$Janux Therapeutics(JANX)$